Table 2 Meta-analyses on preoperative treatment (RT; RTCT; CT) versus surgery
Primary tumor site | Range of recruitment periods | N° trial | N° trial | N° total pts | N° pts RT±CT arms | N° pts CT arms | N° pts surgery arms | Dose range (Gy) | Hystology | Hazard ratio | SVV benefit | SVV benefit | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Including RT | (95% CI ; p) | 2 yy | 5 yy | ||||||||||
Arnott[42] | Esophagus | 1973-1988 | 5 | 5 | 1147 | 573 | - | 574 | 20-40 | SCC-86% | 0.89 | 4% | 3% |
(520 RT alone + 53 RTCT) | ADC-14% | (CI 0.78-1.01; p=0.06) | |||||||||||
Fiorica[47] | Esophagus | 1983-1995 | 6 | 6 | 764 | 385 | - | 379 | 20-45 | SCC-76% | 0.53 | NS | NS |
ADC-24% | (CI 0.31-0.92; p=0.03) | ||||||||||||
Sjoquist[39] | Esophagus | 1982-2008 | 24 | 14 | 4188 | 1079 | 1046 | 2063 | 20-50.4 | SCC-48.9% | RTCT: 0.78 | RTCT: 8.7% | NR |
(CI 0.70-0.88; p<0.0001) | |||||||||||||
ADC-35.5% | CT: 0.87 | CT: 5.1% | |||||||||||
(CI 0.79-0.96; p=0.005) | |||||||||||||
RTCT vs CT: 0.88 | |||||||||||||
(CI 0.76-1.01; p=0.07) | |||||||||||||
Ronellenfitsch[16] | Esophagus + Stomach + GEJ | 1987-2004 | 14 | 4 | 2422 | 198 | 1024 | 1200 | 35-50.4 | SCC-0% | CT (±RT):0.81 | NS | CT (±RT):9% |
(CI 0.73-0.89; p<0.0001) | |||||||||||||
ADC-100% | RTCT: 0.70 | ||||||||||||
(CI 0.50-0.99; p=0.38) | |||||||||||||
CT: 0.83 | |||||||||||||
(CI 0.75-0.91; p=0.38) |